top of page

Johnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical

Safi Bello

Johnson & Johnson press release ------ At a meeting today with industry analysts, senior leaders of Johnson & Johnson and its Janssen Pharmaceutical Companies will announce plans to launch or file for regulatory approval more than 10 new products with blockbuster potential between 2017 and 2021, as well as 50-plus line extensions of existing and new medicines that will bring the company’s transformational medicines to an even broader patient population. The company will also share its plans to continue driving sustainable growth by leveraging its strong portfolio of core blockbuster products, the industry-leading productivity of its innovation model, and the pending acquisition of Swiss-based biotech company Actelion. To get more in depth information click on the picture below to read the release.

Johnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting - Read More from Johnson & Johnson

 
 
Featured Posts
Recent Posts
Follow Us
  • Instagram
  • Pinterest
  • Tumblr Social Icon

© 2025 Safi Bello A Girls How To Guide

bottom of page